Home » Newsletters » BioWorld Science

BioWorld Science

June 27, 2012

View Archived Issues

Allergan divulges new S1P1 receptor ligands

Scientists at Exelixis design novel inhibitors of protein kinases

Mavoglurant studies reported at various conferences

CC-223 well tolerated in early-stage clinical study

Promising first-in-human results disclosed for CH-5132799

New Acceleron Pharma drug reduces anemia in model of myelodysplastic syndromes

New levodopa prodrugs presented by Ono Pharmaceutical

New acetyl-CoA carboxylase inhibitors prepared in Japan

Bispecific tetravalent cancer immunotherapic is efficacious and safe in vivo

Sirnaomics awarded NIH grant for siRNA therapeutic

PPI-668 shows promise in patients with HCV infection

Nissan Chemical Industry reports novel anticancer agents

Researchers at Esteve synthesize new agents for pain

Dosing begins in RXI-109 dermal scarring study

Roche decides against exercising opt-in rights to Biotie drug

FDA sets PDUFA date for Heplisav BLA

CHMP issues opinion on subcutaneous use of Velcade

Preclinical development of leishmaniasis vaccine complete

Medivir and Swedish University of Agricultural Sciences launch collaboration

Cellceutix set to kick off phase I trial of Kevetrin

Fuji Film Pharma acquires Japanese marketing rights for three products from Bayer Yakuhin

Astellas Pharma submits MAA for enzalutamide

NICE recommends new treatment options for prostate and lung cancer

Novel S1P4 receptor ligands disclosed

BioSpecifics Technologies commences phase II Xiaflex trial

New NanoTherm research agreement initiated

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...